Tokyo Tape
Sign in
← PeptiDream

Quarterly report · Q2

4587.TEDINET S100OZ1E
Period2022-01-01 → 2022-06-30
Filed2022-08-10
StandardIFRS
ConsolidatedYes
Data checks17 of 17 passed
Key figures · 65
MetricValuePeriodScopeSource row
Revenue¥5.0bn2022-01-01 → 2022-06-30Cons.Revenue IFRS
Revenue¥4.6bn2022-04-01 → 2022-06-30dCons.Revenue IFRS
Revenue¥9.4bn2021-01-01 → 2021-12-31Cons.Revenue IFRS (5-year summary)
Revenue¥2.9bn2021-01-01 → 2021-06-30Cons.Revenue IFRS
Revenue¥1.4bn2021-04-01 → 2021-06-30dCons.Revenue IFRS
Operating income−¥1.6bn2022-01-01 → 2022-06-30Cons.Operating profit loss IFRS
Operating income−¥393m2022-04-01 → 2022-06-30dCons.Operating profit loss IFRS
Operating income¥436m2021-01-01 → 2021-06-30Cons.Operating profit loss IFRS
Operating income¥442m2021-04-01 → 2021-06-30dCons.Operating profit loss IFRS
Profit before tax−¥1.5bn2022-01-01 → 2022-06-30Cons.Profit loss before tax IFRS
Profit before tax−¥361m2022-04-01 → 2022-06-30dCons.Profit loss before tax IFRS
Profit before tax¥3.8bn2021-01-01 → 2021-12-31Cons.Profit loss before tax IFRS (5-year summary)
Profit before tax¥312m2021-01-01 → 2021-06-30Cons.Profit loss before tax IFRS
Profit before tax¥352m2021-04-01 → 2021-06-30dCons.Profit loss before tax IFRS
Net income (owners)−¥1.1bn2022-01-01 → 2022-06-30Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)−¥227m2022-04-01 → 2022-06-30dCons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥2.6bn2021-01-01 → 2021-12-31Cons.Profit loss attributable to owners of parent IFRS (5-year summary)
Net income (owners)−¥8m2021-01-01 → 2021-06-30Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥213m2021-04-01 → 2021-06-30dCons.Profit loss attributable to owners of parent IFRS
Net income−¥1.1bn2022-01-01 → 2022-06-30Cons.Profit loss IFRS
Net income−¥227m2022-04-01 → 2022-06-30dCons.Profit loss IFRS
Net income¥2.6bn2021-01-01 → 2021-12-31Cons.Profit loss IFRS (5-year summary)
Net income−¥8m2021-01-01 → 2021-06-30Cons.Profit loss IFRS
Net income¥213m2021-04-01 → 2021-06-30dCons.Profit loss IFRS
Total assets¥51.9bnat 2022-06-30Cons.Assets IFRS
Total assets¥27.0bnat 2021-12-31Cons.Assets IFRS
Total assets¥24.8bnat 2021-06-30Cons.Total assets IFRS (5-year summary)
Total assets¥26.1bnat 2020-12-31dCons.Assets IFRS
Total liabilities¥27.2bnat 2022-06-30Cons.Liabilities IFRS
Total liabilities¥1.7bnat 2021-12-31Cons.Liabilities IFRS
Total liabilities¥4.9bnat 2020-12-31dCons.Liabilities IFRS
Net assets / equity¥24.7bnat 2022-06-30Cons.Equity IFRS
Net assets / equity¥25.4bnat 2021-12-31Cons.Equity IFRS
Net assets / equity¥22.6bnat 2021-06-30Cons.Equity IFRS
Net assets / equity¥21.3bnat 2020-12-31dCons.Equity IFRS
Equity (owners)¥24.7bnat 2022-06-30Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥25.4bnat 2021-12-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥22.6bnat 2021-06-30Cons.Equity attributable to owners of parent IFRS (5-year summary)
Equity (owners)¥21.3bnat 2020-12-31dCons.Equity attributable to owners of parent IFRS
Cash & equivalents¥6.4bnat 2022-06-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥11.7bnat 2021-12-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥11.8bnat 2021-06-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥7.1bnat 2020-12-31dCons.Cash and cash equivalents IFRS
Operating cash flow−¥10m2022-01-01 → 2022-06-30Cons.Net cash provided by used in operating activities IFRS
Operating cash flow¥6.7bn2021-01-01 → 2021-12-31Cons.Cash flows from used in operating activities IFRS (5-year summary)
Operating cash flow¥5.0bn2021-01-01 → 2021-06-30Cons.Net cash provided by used in operating activities IFRS
Investing cash flow−¥26.7bn2022-01-01 → 2022-06-30Cons.Net cash provided by used in investing activities IFRS
Investing cash flow−¥2.3bn2021-01-01 → 2021-12-31Cons.Cash flows from used in investing activities IFRS (5-year summary)
Investing cash flow−¥450m2021-01-01 → 2021-06-30Cons.Net cash provided by used in investing activities IFRS
Financing cash flow¥21.6bn2022-01-01 → 2022-06-30Cons.Net cash provided by used in financing activities IFRS
Financing cash flow¥66m2021-01-01 → 2021-12-31Cons.Cash flows from used in financing activities IFRS (5-year summary)
Financing cash flow¥45m2021-01-01 → 2021-06-30Cons.Net cash provided by used in financing activities IFRS
EPS (basic)¥-8.132022-01-01 → 2022-06-30Cons.Basic earnings loss per share IFRS
EPS (basic)¥-1.752022-04-01 → 2022-06-30dCons.Basic earnings loss per share IFRS
EPS (basic)¥19.962021-01-01 → 2021-12-31Cons.Basic earnings loss per share IFRS (5-year summary)
EPS (basic)¥-0.072021-01-01 → 2021-06-30Cons.Basic earnings loss per share IFRS
EPS (basic)¥1.662021-04-01 → 2021-06-30dCons.Basic earnings loss per share IFRS
EPS (diluted)¥-8.132022-01-01 → 2022-06-30Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥-1.752022-04-01 → 2022-06-30dCons.Diluted earnings loss per share IFRS
EPS (diluted)¥19.812021-01-01 → 2021-12-31Cons.Diluted earnings loss per share IFRS (5-year summary)
EPS (diluted)¥-0.072021-01-01 → 2021-06-30Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥1.642021-04-01 → 2021-06-30dCons.Diluted earnings loss per share IFRS
Equity ratio47.7%at 2022-06-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio93.8%at 2021-12-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio91.3%at 2021-06-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 9
SegmentItemPeriodValue
jpcrp040300-q2r_E27486-000Drug Discovery And Development Businessreportable segmentrevenue2022-01-01 → 2022-06-30¥1.1bn
jpcrp040300-q2r_E27486-000Drug Discovery And Development Businessreportable segmentrevenue external2022-01-01 → 2022-06-30¥1.1bn
jpcrp040300-q2r_E27486-000Drug Discovery And Development Businessreportable segmentsegment profit2022-01-01 → 2022-06-30−¥1.4bn
jpcrp040300-q2r_E27486-000Radiopharmaceuticals Businessreportable segmentrevenue2022-01-01 → 2022-06-30¥3.9bn
jpcrp040300-q2r_E27486-000Radiopharmaceuticals Businessreportable segmentrevenue external2022-01-01 → 2022-06-30¥3.9bn
jpcrp040300-q2r_E27486-000Radiopharmaceuticals Businessreportable segmentsegment profit2022-01-01 → 2022-06-30¥198m
—segment totalrevenue2022-01-01 → 2022-06-30¥5.0bn
—segment totalrevenue external2022-01-01 → 2022-06-30¥5.0bn
—segment totalsegment profit2022-01-01 → 2022-06-30−¥1.2bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 668
ItemContextValueUnit
Assets IFRSCurrentQuarterInstant51895583000JPY
Trade and other payables cl IFRSPrior2YearInstant2562788000JPY
Trade and other payables cl IFRSPrior1YearInstant886124000JPY
Trade and other payables cl IFRSCurrentQuarterInstant2890047000JPY
Borrowings cl IFRSPrior2YearInstant－JPY
Borrowings cl IFRSPrior1YearInstant－JPY
Borrowings cl IFRSCurrentQuarterInstant2187893000JPY
Other financial liabilities cl IFRSPrior2YearInstant－JPY
Other financial liabilities cl IFRSPrior1YearInstant－JPY
Other financial liabilities cl IFRSCurrentQuarterInstant291658000JPY
Income taxes payable cl IFRSPrior2YearInstant1586784000JPY
Income taxes payable cl IFRSPrior1YearInstant14404000JPY
Income taxes payable cl IFRSCurrentQuarterInstant20258000JPY
Provisions cl IFRSPrior2YearInstant－JPY
Provisions cl IFRSPrior1YearInstant－JPY
Provisions cl IFRSCurrentQuarterInstant10962000JPY
Other current liabilities cl IFRSPrior2YearInstant712595000JPY
Other current liabilities cl IFRSPrior1YearInstant475517000JPY
Other current liabilities cl IFRSCurrentQuarterInstant964283000JPY
Total current liabilities IFRSPrior2YearInstant4862168000JPY
Total current liabilities IFRSPrior1YearInstant1376047000JPY
Total current liabilities IFRSCurrentQuarterInstant6365102000JPY
Borrowings ncl IFRSPrior2YearInstant－JPY
Borrowings ncl IFRSPrior1YearInstant－JPY
Borrowings ncl IFRSCurrentQuarterInstant19453605000JPY
Other financial liabilities ncl IFRSPrior2YearInstant－JPY
Other financial liabilities ncl IFRSPrior1YearInstant－JPY
Other financial liabilities ncl IFRSCurrentQuarterInstant436583000JPY
Deferred tax liabilities IFRSPrior2YearInstant－JPY
Deferred tax liabilities IFRSPrior1YearInstant308298000JPY
Deferred tax liabilities IFRSCurrentQuarterInstant756368000JPY
Retirement benefit liability ncl IFRSPrior2YearInstant－JPY
Retirement benefit liability ncl IFRSPrior1YearInstant－JPY
Retirement benefit liability ncl IFRSCurrentQuarterInstant144570000JPY
Non current labilities IFRSPrior2YearInstant－JPY
Non current labilities IFRSPrior1YearInstant308298000JPY
Non current labilities IFRSCurrentQuarterInstant20791128000JPY
Liabilities IFRSPrior2YearInstant4862168000JPY
Liabilities IFRSPrior1YearInstant1684345000JPY
Liabilities IFRSCurrentQuarterInstant27156230000JPY
Share capital IFRSPrior2YearInstant3933885000JPY
Share capital IFRSPrior1YearInstant3956738000JPY
Share capital IFRSCurrentQuarterInstant3956738000JPY
Capital surplus IFRSPrior2YearInstant10305306000JPY
Capital surplus IFRSPrior1YearInstant4452358000JPY
Capital surplus IFRSCurrentQuarterInstant4451502000JPY
Treasury shares IFRSPrior2YearInstant-655383000JPY
Treasury shares IFRSPrior1YearInstant-620123000JPY
Treasury shares IFRSCurrentQuarterInstant-607255000JPY
Retained earnings IFRSPrior2YearInstant7503531000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 17 of 17 passed
balance sheet identityconsolidated 2020-12-31pass
balance sheet identityconsolidated 2021-12-31pass rounding
balance sheet identityconsolidated 2022-06-30pass rounding
dei present pass
period resolution pass
statement vs summary · net income attributable to parentconsolidated 2021-01-01/2021-06-30pass
statement vs summary · net income attributable to parentconsolidated 2021-04-01/2021-06-30pass
statement vs summary · net income attributable to parentconsolidated 2022-01-01/2022-06-30pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-06-30pass
statement vs summary · operating cash flowconsolidated 2021-01-01/2021-06-30pass
statement vs summary · operating cash flowconsolidated 2022-01-01/2022-06-30pass
statement vs summary · revenueconsolidated 2021-01-01/2021-06-30pass
statement vs summary · revenueconsolidated 2021-04-01/2021-06-30pass
statement vs summary · revenueconsolidated 2022-01-01/2022-06-30pass
statement vs summary · revenueconsolidated 2022-04-01/2022-06-30pass
statement vs summary · total assetsconsolidated 2021-12-31pass
statement vs summary · total assetsconsolidated 2022-06-30pass